Allogenica received a €2.5 million grant from the French government 's France 2030 program  to support the industrialization of its...

New Leadership Appointments: Allogenica appoints Tobias Abel, PhD, formerly with Sangamo Therapeutics, as Chief Scientific Officer and...

Connect with Inna Menkova at the 9th CAR-TCR Summit

We are pleased to announce that the R&D collaborative projet between Allogenica and its academic partner Dr Julien MARIE’s team, based in...

Allogenica was representerd in London 19-20 March, 2024 for the Advanced Therapies congress.

Allogenica was represented in Grenoble for iVenture and Tech&Fest on February 1-2, 2024. Dr Inna Menkova, CEO, presented the company to...

This is a significant milestone in Allogenica's journey, characterized by enlarged Laboratory space, specially designed to host our...

Allogenica's heart and soul is innovation. The innovation that we wish to bring to patients by developing allogeneic CAR-T immediately...

We are honored to be Clara “proof of concept” recipient. This project arose from interactions between Dr. Inna MENKOVA and Dr. Julien...

Inna MENKOVA, CEO of Allogenica, was yesterday awarded the "Femme de la Tech" prize at the 20th edition of the "Décideures" competition...

Inna MENKOVA, CEO of Allogenica, was honored to receive the « Medical biotech & pharmaceuticals » award and to be in the top 3 finalists...

Yesterday, Allogenica's co-founders Inna MENKOVA and Jean-Guillaume Lafay went to Cité des sciences et de l'industrie to receive and...

Founded in January 2022, Allogenica is dedicated to developing universal CAR-T cell-therapies to treat cancers, particularly blood...

Founded in January 2022, Allogenica specialized in the development of universal Chimeric Antigen Receptor T-cell-therapies (CAR-T...